CCND1 and mantle cell lymphoma: EPA, a key regulator of cyclin D1 synthesis, has been suggested to be of therapeutic potential in patients with mantle cell lymphoma since the main culprit in the pathogenesis and refractoriness of this type of malignancy is the elevated levels of cyclin D1 which is crucial in cell cycle progression from G1 to the S phase [61, 62].